# A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia

> **NCT01055483** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 59 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** panobinostat/LBH589B

## Key facts

- **NCT ID:** NCT01055483
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01055483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01055483, "A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01055483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*